Bombesin is a widely expressed in the CNS and GI tract and has a wide range of physiological functions.Contains N-terminal pyroglutamyl.
Catalogue number crb1000583 Molecular Weight 1618.8 Sequence (one letter code)
Sequence (three letter code)
Modifications where Pyr is pyroglutamyl Purity >95% cas 31362-50-2 Storage -20°C References
Shimizu et al (2016) A Stress-Related Peptide Bombesin Centrally Induces Frequent Urination through Brain Bombesin Receptor Types 1 and 2 in the Rat. J. Pharmacol. Exp. Ther. 356(3) 693 PMID: 26729307.
Sancho et al (2011) Bombesin Receptor-Mediated Imaging and Cytotoxicity: Review and Current Status. Curr. Drug Deliv. 8(1) 79 PMID: 21034419.
Manufactured in: United Kingdom
Bombesin-like peptides are involved in many physiological functions including: regulation of food intake; anxiety and fear–related behaviour; thermoregulation; stress response; learning and memory and in the stimulation of smooth muscle contraction. Bombesin is also a tumour marker for small cell carcinoma in the lung; gastric cancer; pancreatic cancer, and neuroblastoma.
The receptors for these two peptides are G-protein-coupled receptors known as bombesin receptor type 1 (BB1; also known as NMB receptor) and bombesin receptor type 2 (BB2; also known as GRP- receptor). Bombesin shows high affinity to both of these receptor subtypes. These bombesin-like peptides and their receptors are widely distributed in the central nervous system (CNS) and gastrointestinal (GI) tract.
This peptide contains an N-terminal pyroglutamyl to prevent the intramolecular cyclisation of the N-terminal of glutamine to N‐pyroglutamate (pGlu).